Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma-Reference-Cited by-同舟云学术

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

Published:2001-12-28 Issue:1 Volume:94 Page:25-36
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Harris Lyndsay,Batist Gerald,Belt Robert,Rovira Douglas,Navari Rudolph,Azarnia Nozar,Welles Lauri,Winer Eric,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference31 articles.

1. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

2. Randomized Trial of Doxorubicin, Bisantrene, and Miltoxantrone in Advanced Breast Cancer: A Southwest Oncology Group Study

3. Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

4. Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

5. Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8

Cited by 442 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study;Nanomedicine: Nanotechnology, Biology and Medicine;2024-11

2. A Robust Chromatographic Method for Drug Release profiling of liposomal doxorubicin HCl;Journal of Pharmaceutical Sciences;2024-09

3. A Comprehensive Update on Nanoparticle in Targeting of Skin Cancer Therapy: Recent Updates, Challenges, and Future Perspectives;Research Journal of Pharmacy and Technology;2024-06-25

4. All-Rounder Liposomes in Cancer Immunotherapy: Strategies and Design Applications of Engineered Liposomal Nanomaterials;BioChip Journal;2024-04-03

5. A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins;Scientific Reports;2024-03-01